These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21160410)

  • 61. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.
    Cysique LA; Brew BJ
    Neuropsychol Rev; 2009 Jun; 19(2):169-85. PubMed ID: 19424802
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: the NEU screen.
    Muñoz-Moreno JA; Prats A; Pérez-Álvarez N; Fumaz CR; Garolera M; Doval E; Negredo E; Ferrer MJ; Clotet B;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):585-92. PubMed ID: 24135776
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India.
    Ghate M; Mehendale S; Meyer R; Umlauf A; Deutsch R; Kamat R; Thakar M; Risbud A; Kulkarni S; Sakamoto M; Alexander T; Franklin D; Letendre S; Heaton RK; Grant I; Marcotte TD
    J Neurovirol; 2015 Aug; 21(4):391-8. PubMed ID: 25750072
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Diagnostic and prognostic biomarkers for HAND.
    McLaurin KA; Booze RM; Mactutus CF
    J Neurovirol; 2019 Oct; 25(5):686-701. PubMed ID: 30607890
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Editorial commentary: cerebrospinal fluid inhibitory quotients of antiretroviral drugs.
    Fletcher CV
    Clin Infect Dis; 2015 Jan; 60(2):318-20. PubMed ID: 25281611
    [No Abstract]   [Full Text] [Related]  

  • 66. HIV and age do not substantially interact in HIV-associated neurocognitive impairment.
    Cysique LA; Maruff P; Bain MP; Wright E; Brew BJ
    J Neuropsychiatry Clin Neurosci; 2011; 23(1):83-9. PubMed ID: 21304143
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.
    Giunta B; Ehrhart J; Obregon DF; Lam L; Le L; Jin J; Fernandez F; Tan J; Shytle RD
    Mol Brain; 2011 Jun; 4(1):23. PubMed ID: 21649911
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.
    Rosenthal J; Tyor W
    J Neurovirol; 2019 Oct; 25(5):673-685. PubMed ID: 30868422
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HIV and the brain.
    Highleyman L
    BETA; 2009; 21(4):16-29. PubMed ID: 20034243
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.
    Spudich S; González-Scarano F
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007120. PubMed ID: 22675662
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Central Nervous System Effects of Early HIV Infection and Consequences of Antiretroviral Therapy Initiation during Acute HIV.
    Chan P; Spudich S
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066244
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Associative and predictive biomarkers of dementia in HIV-1-infected patients.
    Bandaru VV; McArthur JC; Sacktor N; Cutler RG; Knapp EL; Mattson MP; Haughey NJ
    Neurology; 2007 May; 68(18):1481-7. PubMed ID: 17470750
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.
    Kalayjian RC; Robertson KR; Albert JM; Fichtenbaum CJ; Brown TT; Taiwo BO;
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):e49-e54. PubMed ID: 30939531
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Cognitive alterations associated with HIV-1 infection and AIDS].
    Christo PP
    Rev Assoc Med Bras (1992); 2010; 56(2):242-7. PubMed ID: 20499003
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HIV-associated neurocognitive disorder.
    Smail RC; Brew BJ
    Handb Clin Neurol; 2018; 152():75-97. PubMed ID: 29604986
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.
    Ferretti F; Gisslen M; Cinque P; Price RW
    Curr HIV/AIDS Rep; 2015 Jun; 12(2):280-8. PubMed ID: 25860317
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evolving clinical phenotypes in HIV-associated neurocognitive disorders.
    Sacktor N; Robertson K
    Curr Opin HIV AIDS; 2014 Nov; 9(6):517-20. PubMed ID: 25203640
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.
    Ances BM; Clifford DB
    Curr Neurol Neurosci Rep; 2008 Nov; 8(6):455-61. PubMed ID: 18957181
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?
    Underwood J; Robertson KR; Winston A
    AIDS; 2015 Jan; 29(3):253-61. PubMed ID: 25426811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effort and neuropsychological performance in HIV-infected individuals on stable combination antiretroviral therapy.
    Paul R; Rhee G; Baker LM; Vaida F; Cooley SA; Ances BM
    J Neurovirol; 2017 Oct; 23(5):725-733. PubMed ID: 28895090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.